The analysis of samples containing Respiratory Syncytial Virus (RSV) in clinical trials is notoriously challenging due to the virus's inherent instability. hVIVO’s proprietary Stabilization Transport ...

The prevention of respiratory syncytial virus (RSV) has seen incredible advancement in the past few years. In this editorially independent package, Scientific American explores breakthroughs in ...

Respiratory Syncytial Virus (RSV) is a common childhood disease. Most people catch and recover from it by the age of three.

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization ...

Nirsevimab significantly reduced respiratory syncytial virus (RSV)–associated hospitalizations in infants during the 2024-2025 season, consistent with previous findings. The study used a large dataset ...